Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In-Vivo Animal Testing
Inspira Technologies (Nasdaq: IINN) has announced a significant breakthrough in the in-vivo testing of its VORTX™ technology, achieving above 99% gas exchange efficiency at a defined flow rate. The testing was conducted on an 80 kg swine at Israel's Institute of Animal Research as part of an Israel Innovation Authority-funded initiative.
The VORTX technology, designed to oxygenate blood without the trauma associated with conventional hollow fiber technologies, will be integrated into Inspira's pipeline, including the INSPIRA ART500. The system's unique design maintains zero-pressure difference during oxygenation, potentially reducing harmful blood trauma commonly seen in traditional fiber-based oxygenators.
This successful in-vivo experiment validates previous lab-based findings, demonstrating proof-of-concept and scalability. The company plans to continue evaluating and refining the VORTX oxygen delivery technology, with additional results expected in the near future.
Inspira Technologies (Nasdaq: IINN) ha annunciato un'importante svolta nei test in vivo della sua tecnologia VORTX™, raggiungendo un'efficienza di scambio gassoso superiore al 99% a una portata definita. Il test è stato condotto su un suino di 80 kg presso l'Istituto di Ricerca Animale di Israele, nell'ambito di un'iniziativa finanziata dall'Autorità per l'Innovazione di Israele.
La tecnologia VORTX, progettata per ossigenare il sangue senza il trauma associato alle tradizionali tecnologie a fibre cave, sarà integrata nel portafoglio di Inspira, incluso il INSPIRA ART500. Il design unico del sistema mantiene una differenza di pressione pari a zero durante l'ossigenazione, riducendo potenzialmente il danno ematico spesso osservato negli ossigenatori convenzionali a fibre.
Questo esperimento in vivo di successo conferma i risultati ottenuti in laboratorio, dimostrando la validità del concetto e la possibilità di scalare la tecnologia. L'azienda prevede di continuare a valutare e perfezionare la tecnologia di erogazione dell'ossigeno VORTX, con ulteriori risultati attesi a breve.
Inspira Technologies (Nasdaq: IINN) ha anunciado un avance significativo en las pruebas in vivo de su tecnología VORTX™, alcanzando una eficiencia de intercambio gaseoso superior al 99% a un caudal definido. Las pruebas se realizaron en un cerdo de 80 kg en el Instituto de Investigación Animal de Israel, como parte de una iniciativa financiada por la Autoridad de Innovación de Israel.
La tecnología VORTX, diseñada para oxigenar la sangre sin el trauma asociado con las tecnologías convencionales de fibras huecas, se integrará en la cartera de Inspira, incluido el INSPIRA ART500. El diseño único del sistema mantiene una diferencia de presión nula durante la oxigenación, lo que podría reducir el daño sanguíneo perjudicial común en los oxigenadores tradicionales basados en fibras.
Este exitoso experimento in vivo valida hallazgos previos en laboratorio, demostrando la prueba de concepto y la escalabilidad. La empresa planea continuar evaluando y perfeccionando la tecnología de suministro de oxígeno VORTX, con resultados adicionales esperados en un futuro próximo.
Inspira Technologies(나스닥: IINN)는 VORTX™ 기술의 생체 내 테스트에서 99% 이상의 가스 교환 효율을 특정 유량에서 달성하는 중요한 돌파구를 발표했습니다. 이 테스트는 이스라엘 동물 연구소에서 80kg 돼지를 대상으로 이스라엘 혁신청의 지원을 받아 진행되었습니다.
VORTX 기술은 기존의 중공섬유 기술과 관련된 혈액 손상 없이 혈액에 산소를 공급하도록 설계되었으며, Inspira의 제품군에 포함되어 INSPIRA ART500에도 통합될 예정입니다. 이 시스템의 독특한 설계는 산소 공급 중 압력 차이를 0으로 유지하여 전통적인 섬유 기반 산소 공급기에서 흔히 발생하는 혈액 손상을 줄일 수 있습니다.
이번 성공적인 생체 내 실험은 이전 실험실 결과를 검증하며 개념 증명과 확장 가능성을 보여줍니다. 회사는 VORTX 산소 전달 기술을 계속 평가하고 개선할 계획이며, 추가 결과는 가까운 시일 내에 발표될 예정입니다.
Inspira Technologies (Nasdaq : IINN) a annoncé une avancée majeure dans les tests in vivo de sa technologie VORTX™, atteignant une efficacité d’échange gazeux supérieure à 99 % à un débit défini. Les tests ont été réalisés sur un porc de 80 kg à l’Institut de Recherche Animale d’Israël, dans le cadre d’une initiative financée par l’Autorité israélienne de l’innovation.
La technologie VORTX, conçue pour oxygéner le sang sans le traumatisme associé aux technologies conventionnelles à fibres creuses, sera intégrée dans la gamme de produits d’Inspira, y compris le INSPIRA ART500. La conception unique du système maintient une différence de pression nulle lors de l’oxygénation, réduisant potentiellement les traumatismes sanguins nocifs fréquemment observés avec les oxygénateurs traditionnels à fibres.
Cette expérience in vivo réussie valide les résultats précédemment obtenus en laboratoire, démontrant la preuve de concept et la possibilité de montée en échelle. L’entreprise prévoit de poursuivre l’évaluation et l’amélioration de la technologie de distribution d’oxygène VORTX, avec d’autres résultats attendus prochainement.
Inspira Technologies (Nasdaq: IINN) hat einen bedeutenden Durchbruch bei In-vivo-Tests seiner VORTX™-Technologie bekannt gegeben und dabei eine Gasaustauscheffizienz von über 99 % bei einer definierten Durchflussrate erreicht. Die Tests wurden an einem 80 kg schweren Schwein am Israelischen Institut für Tierforschung im Rahmen einer von der Israelischen Innovationsbehörde geförderten Initiative durchgeführt.
Die VORTX-Technologie, die entwickelt wurde, um Blut ohne die mit herkömmlichen Hohlfasertechnologien verbundenen Traumata zu oxygenieren, wird in Inspiras Produktpipeline integriert, einschließlich des INSPIRA ART500. Das einzigartige Design des Systems sorgt während der Oxygenierung für einen Druckunterschied von null, was potenziell schädliche Bluttraumata reduziert, die bei herkömmlichen faserbasierten Oxygenatoren häufig auftreten.
Dieses erfolgreiche In-vivo-Experiment bestätigt frühere Laborergebnisse und demonstriert den Machbarkeitsnachweis sowie die Skalierbarkeit. Das Unternehmen plant, die VORTX-Sauerstoffversorgungstechnologie weiterhin zu evaluieren und zu optimieren, wobei in naher Zukunft weitere Ergebnisse erwartet werden.
- Achieved above 99% gas exchange efficiency in animal testing
- Successfully validated previous lab-based findings with in-vivo testing
- Received funding support from Israel Innovation Authority
- Technology shows potential for reduced blood trauma compared to traditional oxygenators
- Product still in testing phase, not yet commercially available
- Further evaluation and refinement needed before market readiness
Insights
Inspira's VORTX achieves crucial 99% gas exchange efficiency in animal testing, marking significant progress for their respiratory support technology.
The achievement of
What makes VORTX particularly notable is its design approach. Unlike conventional hollow fiber oxygenators that can cause hemolysis and inflammatory responses, VORTX utilizes a zero-pressure difference mechanism during oxygenation. This engineering approach could potentially reduce blood trauma, addressing a major limitation in current extracorporeal oxygenation systems.
The testing location at Israel's premier large-animal preclinical research facility adds credibility to these results, as does the Israel Innovation Authority funding, which typically requires rigorous scientific validation. This successful in-vivo confirmation of earlier lab findings demonstrates both proof-of-concept and scalability - two crucial hurdles in medical device development.
For context, this represents an early but important validation point in the development pathway. The technology is slated for integration into the INSPIRA ART500, positioning it as an alternative to invasive mechanical ventilation for acute respiratory failure patients. However, considerable development work, human trials, and regulatory approvals still lie ahead before potential commercialization.
Successful animal testing of VORTX technology represents significant de-risking for Inspira's core platform, enhancing its competitive positioning.
This milestone achievement in VORTX technology represents a significant technical validation for Inspira Technologies, a company with a market capitalization of approximately
The successful in-vivo testing underscores progress in Inspira's respiratory support technology pipeline, specifically for the INSPIRA ART500 system targeting acute respiratory failure patients who might otherwise require invasive mechanical ventilation. This addresses a substantial clinical need, as conventional respiratory support technologies often present complications from blood trauma and inflammatory responses.
The Israel Innovation Authority funding support provides two key advantages: non-dilutive capital preserving shareholder value and independent validation through a government agency's scientific review. For a company trading at
While this technological milestone demonstrates promising progress, investors should recognize that the development pathway for novel medical devices remains lengthy and capital-intensive. The announcement indicates further evaluation and refinement ahead, with additional results expected "in the near future." This suggests continued R&D investment will be required before commercialization becomes possible.
RA'ANANA, Israel, April 23, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a major milestone achievement in the in-vivo testing of its next-generation VORTX™ technology. This breakthrough innovation is uniquely designed to oxygenate blood effectively without the trauma associated with conventional hollow fiber technologies. The in vivo testing achieved above
The VORTX technology, slated for integration into Inspira’s pipeline, including the INSPIRA ART500, aims to transform acute respiratory care, providing an advanced alternative for patients who might otherwise require invasive mechanical ventilation. The distinctive design of the VORTX is meant to ensure a zero-pressure difference during the oxygenation process, potentially reducing levels of harmful blood trauma, a prevalent limitation in traditional fiber-based oxygenators.
This critical in-vivo experiment was conducted with an 80 kg swine at the renowned Institute of Animal Research, Israel's premier large-animal preclinical research facility, as part of an Israel Innovation Authority ("IIA")-funded initiative. The trial successfully confirmed prior lab-based findings, demonstrating proof-of-concept, scalability, and validating Inspira's continued progress toward its key development objectives.
"We are extremely proud to achieve this major technological milestone," stated Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies. "I believe that the VORTX technology represents a significant leap forward in blood oxygenation, and successfully achieving this milestone within an IIA-funded framework underscores our team's innovative capabilities and strengthens our commitment to advancing life-support technology."
Inspira plans to further evaluate and refine the VORTX oxygen delivery technology, with additional results and development updates anticipated in the near future.
About Inspira Technologies
Inspira Technologies is developing innovative respiratory support and diagnostics technologies. The Company's flagship INSPIRA ART500 system also known as the INSPIRA ART aims to revolutionize critical care by enabling patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation. The FDA-cleared INSPIRA ART100 system has received regulatory approvals for Cardiopulmonary Bypass procedures in both the U.S. and for Cardiopulmonary Bypass procedures and Extra Corporeal Membrane Oxygenation in Israel. The Company's HYLA™ blood sensor technology is designed to provide continuous, real-time blood monitoring without the need for blood draws. The Company's pipeline products, including the INSPIRA ART500, and HYLA blood sensor, are currently in development and have not yet received regulatory approval.
For more information, please visit our corporate website at https://inspira-technologies.com.
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential benefits of the products and designs of the Company’s products and technologies, including its VORTX technology, the believe that the VORTX™ technology represents a significant leap forward in blood oxygenation, and successfully achieving this milestone within an IIA-funded framework underscores its innovative capabilities and strengthens its commitment to advancing life-support technology, its plan to evaluate and refine the VORTX technology and that it expects to share additional results and development updates in the near future. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov.
Company Contact
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
Capital Markets & Investor Contact
Arx | Capital Markets Advisors
North American Equities Desk
inspira@arxadvisory.com
FAQ
What efficiency rate did Inspira's VORTX technology achieve in its latest animal testing?
How does IINN's VORTX technology differ from traditional blood oxygenators?
Where was the VORTX technology testing conducted for IINN stock?
What is the intended application for Inspira's VORTX technology?
